Diabetes in individuals with Tuberous Sclerosis Complex treated with mTOR inhibitors

Tuberous sclerosis complex (TSC) is a genetic disorder that is manifested in multiple body systems. Initiation of an mTOR inhibitor, either everolimus or sirolimus, are now routinely prescribed for multiple clinical manifestations of TSC, including subependymal giant cell astrocytoma and epilepsy. These medications are generally well tolerated. Side effects previously identified in well-designed clinical trials tend to be mild in severity and are readily manageable. Regulatory approvals for; the treatment of TSC have expanded and use of everolimus and sirolimus; clinically, enlarging clinician experience and enabling identification of additional; potential treatment-related effects that are rarer than could be identified or recognized; in previous clinical trials
Source: Pediatric Neurology - Category: Neurology Authors: Tags: Short Communication Source Type: research